Asher Bio News Today

Check out this week’s medical marketing news, dealmaking and industry chatter.

The Claudin-6–directed CAR T-cell therapy, BNT211, showed signs of clinical activity in patients with CLDN6-positive relapsed or refractory solid tumors.

BioSpace is proud to present its NextGen Bio “Class of 2023,” a list of the hottest recently launched life sciences companies in North America. 

Sanofi did not see the efficacy it wanted in mid-stage tests of a cytokine therapy from its $2.5 billion acquisition of Synthorx. While the pharmaceutical giant isn’t giving up on the drug, it said it will restart the molecule in a new Phase 1/2 program, a setback that will lead to a €1.6 billion financial writedown.

Industry veteran brings deep expertise in translational medicine and clinical development in oncologySAN FRANCISCO--(BUSINESS WIRE)--Asher Biotherapeutics, Inc. (Asher Bio), a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announced the appo...

Jazz Pharmaceuticals is licensing rights to a Werewolf Therapeutics cytokine therapy that’s on track to reach clinical testing next year. The deal gives Jazz a drug candidate that expands the company’s scope to immuno-oncology.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announced the appointment of Ian T. Clark to its Board of Directors. Mr. Clark most recently served as Chief Executive Offi...

/PRNewswire/ -- The "Targeted Immunotherapy in Oncology" report has been added to ResearchAndMarkets.coms offering. This research service investigates...

The field of biotechs pursuing new interleukin-2 cancer immunotherapies is filled with companies engineering different versions of that signaling protein. Avenge Bio CEO Mike Heffernan said his startup stands apart with a cell therapy that produces human IL-2 that could offer advantages compared to engineered versions of that protein.

MedCity News Biotech IPO wave rolls on as Werewolf, Vaccitech raise $230M for clinical trials Vaccitech and Werewolf Therapeutics joined the public markets, raising a combined $230 million. The vaccine developer and the cancer immunotherapy biotech will apply the IPO proceeds toward clinical development of their respective pipelines. Shares0   Two more biotech companies are joining the public markets. Werewolf Therapeutics and Vaccitech priced their respective IPOs late Thursday, raising a c...